Why Knee Osteoarthritis Matters
Knee osteoarthritis is one of the most common joint conditions affecting adults. It can lead to pain, stiffness, swelling, reduced mobility, and difficulty with everyday activities such as walking, climbing stairs, exercising, or standing for long periods of time.
Osteoarthritis is often described as a “wear and tear” condition, but the process is more complex. Inflammation, cartilage breakdown, joint stress, changes in the surrounding bone, and reduced repair capacity can all contribute to symptoms and disease progression.
Many current treatments focus on reducing pain and improving mobility. These may include physical therapy, medications, injections, lifestyle changes, and surgery in more advanced cases. While these options can be helpful, researchers continue to study regenerative approaches that may better support the joint environment itself.
One area of growing interest is the use of umbilical cord-origin mesenchymal stem cells, or UC-MSCs.
Why Researchers Are Studying UC-MSCs
Mesenchymal stem cells, or MSCs, are studied in regenerative medicine because they release signaling molecules that may help influence inflammation, immune response, tissue repair, and cell communication.
Umbilical cord-origin MSCs are especially interesting because umbilical cord tissue provides a young and highly active source of MSCs. These cells are being studied for their potential to support cartilage-related repair processes and improve the biological environment inside the joint.
For knee osteoarthritis, UC-MSCs may help support:
- Healthier cartilage cell activity
- Reduced inflammatory signaling
- Improved joint function
- Tissue repair and regeneration pathways
- Better balance in the joint environment
Rather than simply masking symptoms, this area of research looks at how regenerative therapies may influence the underlying processes involved in joint degeneration.
What This Review Examined
This 2025 study was a systematic review and meta-analysis, meaning researchers gathered and analyzed results from multiple clinical studies to better understand the overall evidence.
The authors searched several major databases, including PubMed, Embase, Scopus, Web of Science, ClinicalTrials.gov, and others, for clinical studies involving UC-MSC therapy in people with osteoarthritis.
After screening 1,427 articles, the researchers included 8 studies with a total of 688 participants. These studies included randomized trials, phase I/II studies, and quasi-experimental clinical trials.
The review focused on three main questions:
- Are UC-MSCs safe for patients with knee osteoarthritis?
- Do they improve pain and joint function?
- What dose range may be most effective?
The researchers also grouped treatment doses into low, medium, and high categories to better understand how dosing may influence outcomes.
What the Findings Showed
Overall, the review found encouraging evidence that UC-MSC therapy may support improvements in knee osteoarthritis, especially in joint function and certain pain-related outcomes.
One of the key findings involved the WOMAC score, a common tool used to measure osteoarthritis symptoms such as pain, stiffness, and physical function. The review found improvement in total WOMAC scores at 6 months in the UC-MSC group compared with controls.
Pain scores also moved in a favorable direction at both 6 and 12 months. In the overall analysis, pain reduction showed improvement trends. In subgroup analysis, the researchers found that low-dose UC-MSC treatment was associated with statistically significant pain reduction at both 6 and 12 months.
The review also found that low and medium doses appeared to show stronger results than higher doses or control treatments such as hyaluronic acid or placebo. This is an important finding because it suggests that more cells may not always mean better outcomes. Instead, identifying the right dose may be key for future treatment development.
Safety findings were also encouraging. Across the included studies, the authors reported no serious treatment-related adverse events. Reported side effects were generally mild, temporary, and manageable.
How UC-MSCs May Support Joint Health
UC-MSCs may support joint health through several biological mechanisms. One of the most important is paracrine signaling, which means the cells release helpful molecules that communicate with surrounding tissues.
These signals may help reduce inflammatory activity, support immune balance, and encourage repair-related pathways in the joint. This matters because osteoarthritis involves more than cartilage loss alone. The entire joint environment can become stressed, inflamed, and less able to maintain healthy tissue.
UC-MSCs may also influence cartilage-related cells and the extracellular matrix, which is the structural network that helps cartilage stay strong, smooth, and functional. By supporting a healthier balance between tissue breakdown and repair, UC-MSCs may help create a more favorable environment for joint function.
The study’s dose-related findings are especially interesting because they suggest that UC-MSC therapy may work best when dosing is carefully selected and standardized.
Why This Research Matters
This review is meaningful because it pulls together human clinical research on umbilical cord-origin MSCs for knee osteoarthritis. Instead of looking at one trial alone, it gives a broader view of what the current evidence suggests.
The findings support continued interest in UC-MSCs as a regenerative approach for osteoarthritis, especially for improving function, supporting pain reduction, and maintaining a favorable safety profile.
For patients with knee osteoarthritis, research like this is important because it points toward future therapies that may focus not only on symptom relief, but also on supporting the biological health of the joint.
Looking Ahead
The study highlights the need for continued research with more standardized protocols. Future trials can help clarify the best dosing strategy, ideal treatment schedule, long-term outcomes, and which patients may benefit most.
As research continues, UC-MSC therapy may become an important area of focus in regenerative orthopedic medicine. The review’s findings suggest that umbilical cord-origin MSCs have promising potential for improving joint function and supporting a healthier joint environment.
Takeaway
This systematic review and meta-analysis provides encouraging clinical evidence for the use of umbilical cord-origin MSCs in knee osteoarthritis research. Across the studies reviewed, UC-MSC treatment was associated with improved joint function, favorable pain-related findings, and a strong safety profile.
While future studies will help refine treatment protocols, this research supports the growing interest in UC-MSCs as a regenerative approach for joint support, cartilage health, and improved mobility in knee osteoarthritis.
Source
Lohrasbi E, Babaie S, Hamedfar H, Pourzeinali S, Farshbaf-Khalili A, Toopchizadeh V. Regenerative Therapy in Osteoarthritis Using Umbilical Cord-Origin Mesenchymal Stem Cells: A Critical Appraisal of Clinical Safety and Efficacy Through Systematic Review and Meta-Analysis. Stem Cells International. 2025 Dec 2;2025:4261166. doi: 10.1155/sci/4261166. PMID: 41378180; PMCID: PMC12688636. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12688636/
Related Treatment Pages